Journal profile · CELL & TISSUE ENGINEERING
Stem Cells Translational Medicine
ISSN 2157-6564 · eISSN 2157-6580 · John Wiley and Sons Ltd · UNITED STATES
Stem Cells Translational Medicine: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.85; fully open access; APC about USD 2,822; median 167 days to acceptance (103 articles, last 24 months); community-reported acceptance: easy; 86 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Stem Cells Translational Medicine is published by John Wiley and Sons Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Mesenchymal stem cell research, Pluripotent Stem Cells Research and Tissue Engineering and Regenerative Medicine, together about 45.2% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
STEM CELLS Translational Medicine publishes research spanning the full spectrum of translational stem cell and regenerative medicine, from preclinical validation to clinical implementation. The journal covers: First-in-human studies, early- and late-phase clinical trials, and long-term follow-up or real-world outcomes of stem cell-based and regenerative therapies, including well-substantiated negative clinical findings. Cell-based and stem cell-enabled therapeutic approaches across disease areas, including regenerative medicine, immune therapies, and oncology applications such as hematopoietic stem cell transplantation, stem cell-derived immune therapies, and strategies targeting cancer stem cells. Cell and gene therapies, including stem cell-derived or engineered therapeutics. Technologies enabling the safe, effective, and scalable clinical deployment of cell-based therapies, including delivery systems and combination strategies. Manufacturing science and translational process development, including scale-up, GMP manufacturing, potency assays, quality systems, release criteria, and process analytics supporting clinical-grade cell products. Bioengineering and regenerative technologies, including biomaterials, scaffolds, devices, and tissue engineering strategies that enable therapeutic tissue repair or replacement. Cell tracking, imaging, diagnostics, and delivery technologies that enable monitoring, targeting, and optimization of stem cell-based therapies in clinical or translational settings. Immunological aspects of stem cell and regenerative therapies, including immune compatibility, graft rejection, immune modulation, and tolerance strategies. Stem cell-derived extracellular vesicles, exosomes, and secretome-based therapeutic strategies with translational or clinical potential. Stem cell-derived organoids, assembloids, and advanced 3D tissue models used for disease modeling, drug discovery, and translational therapeutic development. Preclinical models, including advanced in vitro systems and in vivo studies that support the development, safety evaluation, biodistribution, and/or mechanistic understanding of stem cell-based therapies. Pluripotent, fetal, neonatal, post-natal, perinatal, and tissue-specific stem and progenitor cells used in translational or therapeutic research. Cord blood and perinatal cell therapies, including banking strategies, ex vivo expansion, and engineering approaches that support clinical application. Computational, multi-omic
From the journal's Aims & Scope
Research area (LetPub): CELL & TISSUE ENGINEERING
Editor-in-chief Anthony AtalaPublisher website
Editorial board by country: 7 in mainland China (about 21%); most named United Kingdom 8, Mainland China 7, South Korea 3, Japan 2, Italy 2 (34 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Mesenchymal stem cell researchMedicine21.8%
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology13.5%
- Tissue Engineering and Regenerative MedicineMedicine9.9%
- Biomedical Ethics and RegulationMedicine5.2%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology4%
- Neurogenesis and neuroplasticity mechanismsNeuroscience3.8%
- Hematopoietic Stem Cell TransplantationMedicine3.4%
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Cell & Tissue Engineering | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Cell & Tissue Engineering | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Cell & Tissue Engineering | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPMCPubMedEmbaseCASPublisher website
Other: EBSCO
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.85LetPub ·
- Impact factor (publisher) 2025
- 10Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.8Publisher website ·
- CiteScore 2026-06
- 10LetPub ·
- CiteScore (publisher) 2025
- 10Publisher website ·
- SJR 2026-06
- 1.59LetPub ·
- SNIP 2026-06
- 1.19LetPub ·
- h-index
- 53LetPub ·
- h-index
- 133OpenAlex ·
- i10-index
- 1,499OpenAlex ·
- 2-year mean citedness
- 4.58OpenAlex ·
- Self-citation rate
- 1.7%LetPub ·
- Share of gold OA articles
- 99.59%LetPub ·
Volume
- Articles per year
- 71LetPub ·
- Downloads per year (publisher) 2025
- 476,882Publisher website ·
Articles by year OpenAlex count · 2,455 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 85 | 85 | 16 |
| 2025 | 86 | 86 | 276 |
| 2024 | 130 | 130 | 1,088 |
| 2023 | 130 | 130 | 1,682 |
| 2022 | 141 | 141 | 2,724 |
| 2021 | 185 | 185 | 3,832 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
167 daysMedian, submission to acceptance · P25–P75 118 days – 219 days
- Acceptance to online
- —
- Submission to online
- —
- Sample
- 103 articles with submission and acceptance dates (215 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision 2025
- 18 daysPublisher website ·
- Submission to final decision 2025
- 18 daysPublisher website ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,822 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,963 | — | — | |
| LetPub | USD 2,822 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websitePublication ethics
- Publication ethics Committee on Publication Ethics (COPE)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) publicationethics.org
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2157-6564
- Electronic ISSN
- 2157-6580
- Latest issue on the website
- Volume 15, Issue 10 (October 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Stem Cells Translational Medicine
What CAS zone is Stem Cells Translational Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Stem Cells Translational Medicine is in Zone 2 of Medicine, and in Zone 3 of the minor category Cell & Tissue Engineering. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Stem Cells Translational Medicine?
The latest impact factor listed by LetPub is 5.85; CiteScore 10, h-index 133.
How long does peer review take at Stem Cells Translational Medicine?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 167 days (interquartile range 118–219 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Stem Cells Translational Medicine based?
Of the 34 board members whose country the journal's board page names, 7 (about 21%) are in mainland China; the countries named most often are United Kingdom (8), Mainland China (7) and South Korea (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Stem Cells Translational Medicine?
According to LetPub and DOAJ records, Stem Cells Translational Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PMC, PubMed, Embase and CAS; that list has not been checked against each database.
Is Stem Cells Translational Medicine open access, and what is the APC?
Stem Cells Translational Medicine is a fully open-access journal. APC about USD 2,822.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .